D
Douglas C. Wolf
Researcher at Cleveland Clinic
Publications - 86
Citations - 6417
Douglas C. Wolf is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Ulcerative colitis & Adalimumab. The author has an hindex of 23, co-authored 84 publications receiving 5527 citations.
Papers
More filters
Journal ArticleDOI
Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3
Jean-Frederic Colombel,William J. Sandborn,Subrata Ghosh,Douglas C. Wolf,Remo Panaccione,Brian G. Feagan,Walter Reinisch,Anne M. Robinson,Andreas Lazar,Martina Kron,Bidan Huang,Martha Skup,Roopal Thakkar +12 more
TL;DR: Remission, mucosal healing, and improved quality of life were maintained in patients with moderately to severely active UC with long-term adalimumab therapy, for up to 4 years.
Journal ArticleDOI
Quality indicators for inflammatory bowel disease: development of process and outcome measures.
Gil Y. Melmed,Gil Y. Melmed,Corey A. Siegel,Corey A. Siegel,Brennan Spiegel,Brennan Spiegel,John I. Allen,Robert R. Cima,Jean-Frederic Colombel,Themistocles Dassopoulos,Lee A. Denson,Sharon Dudley-Brown,Andrew Garb,Stephen B. Hanauer,Michael D. Kappelman,James D. Lewis,Isabelle Lynch,Amy Moynihan,Amy Moynihan,David T. Rubin,R. Balfour Sartor,Ronald M. Schwartz,Douglas C. Wolf,Thomas A. Ullman +23 more
TL;DR: A set of QIs for IBD was developed with expert interpretation of the literature and multidisciplinary input that focused largely on remission and quality of life, whereas process QIs were aimed at therapeutic optimization and patient safety.
Journal ArticleDOI
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease
Paul Rutgeerts,Christopher Gasink,Daphne Chan,Yinghua Lang,Paul F. Pollack,Jean-Frederic Colombel,Douglas C. Wolf,Douglas Jacobstein,Jewel Johanns,Philippe Szapary,Omoniyi J. Adedokun,Brian G. Feagan,William J. Sandborn +12 more
TL;DR: In an analysis of data from 3 trials of patients with moderate to severe CD, ustekinumab (intravenous induction and subcutaneous maintenance) reduces SES-CD compared with placebo.
Journal ArticleDOI
Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
TL;DR: In this article, the authors investigated whether biologics are detectable in breast milk from women receiving treatment for inflammatory bowel diseases (IBDs) and whether breastfeeding while receiving treatment is associated with infections or developmental delays.
Journal ArticleDOI
Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study.
Kim L. Isaacs,Robert S. Sandler,Maria T. Abreu,Michael F. Picco,Stephen B. Hanauer,Stephen J. Bickston,Daniel H. Present,Francis A. Farraye,Douglas C. Wolf,William J. Sandborn +9 more
TL;DR: A larger trial would be required to determine if rifaximin is effective for the treatment of active pouchitis, but the difference was not significant in this pilot study.